18h
Pharmaceutical Technology on MSNAstraZeneca director says AI must be a “thought partner” in drug discoveryAstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.
AstraZeneca has revealed it has expanded membership of its Senior Executive Team, which comes into effect immediately. The new changes include increased representation of the company’s ...
Judging from its top line, AstraZeneca had a stellar 2024 ... But the British drugmaker did not compensate its CEO accordingly, as Pascal Soriot’s pay package dipped 16% from 17.4 million ...
For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...
Pascal Soriot is the CEO of Astrazeneca. Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the chair of its remuneration ...
One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 ...
Through the program, the company is aiming to establish camizestrant as a new backbone therapy and hit a peak sales target that AstraZeneca CEO Pascal Soriot has set at more than $5 billion.
In another development, AstraZeneca disclosed that top executives, including CEO Pascal Soriot and CFO Aradhana Sarin, have acquired shares following the vesting of a deferred bonus plan. The shares ...
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...
AstraZeneca has agreed to acquire FibroGen ... Astellas licences roxadustat in some markets, including Japan. FibroGen CEO Thane Wettig stated the transaction will support the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results